Skip to main content
. 2020 May 12;41(5):733–755. doi: 10.1210/endrev/bnaa015

Figure 7.

Figure 7.

Afrezza® inhaled insulin. A: Pharmacokinetics profile (baseline corrected serum insulin concentration) of inhaled Afrezza® (8 units) compared to injected insulin lispro (8 units) in 12 subjects with type 1 diabetes. B: Pharmacodynamics profile of inhaled Afrezza® (8 units) compared to injected insulin lispro (10 units) in 25 subjects with type 1 diabetes. Both studies were euglycemic clamp studies. Data from Heinemann L, Baughman R, Boss A, Hompesch M. Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin. J Diabetes Sci Technol. 2017;11(1):148–156.